All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
It was showed the LC13 T cell receptor (TCR), selected for recognition on self-HLA-B(*)0801 bound to a viral peptide, alloreacts with B44 allotypes (HLA-B(*)4402 and HLA-B(*)4405) bound to two different allopeptides. Despite extensive polymorphism between HLA-B(*)0801, HLA-B(*)4402, and HLA-B(*)4405 and the disparate sequences of the viral and allopeptides, the LC13 TCR engaged these peptide-HLA (pHLA) complexes identically, accommodating mimicry of the viral peptide by the allopeptide. The viral and allopeptides adopted similar conformations only after TCR ligation, revealing an induced-fit mechanism of molecular mimicry. The LC13 T cells did not alloreact against HLA-B(*)4403, and the single residue polymorphism between HLA-B(*)4402 and HLA-B(*)4403 affected the plasticity of the allopeptide.
There are currently no customer reviews or questions for Human anti-Peptide EEY T cell receptor (LC13), pCDTCR1 (TCR-YC0892). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION